14-day Premium Trial Subscription Try For FreeTry Free
Q1 2020 Exact Sciences Corp Earnings Call
Exact Sciences (EXAS) delivered earnings and revenue surprises of -5.26% and 0.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

EXACT Sciences Corp. to Host Earnings Call

07:00pm, Wednesday, 06'th May 2020
NEW YORK, NY / ACCESSWIRE / May 6, 2020 / EXACT Sciences Corp. (NASDAQ:EXAS) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 6, 2020 at 5:00 PM Ea
New research from Exact Sciences Corp. (NASDAQ: EXAS) uses real-world-adjusted adherence rates in a colorectal cancer microsimulation, the Colorectal Cancer and Adenoma Incidence and Mortality model (
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Varian (VAR) continued to gain from core Oncology Systems segment in Q2.
Despite the negative earnings trend, a handful of stocks with a favorable Zacks Rank are poised to beat earnings estimates tomorrow.

BF Borgers tops list of new SEC clients again

01:00pm, Monday, 04'th May 2020
EY leads among the largest auditors in the first quarter of 2020.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following investor conference and invited investors to participate by webcast.

2 Cheap Healthcare Stocks to Buy Now

11:36am, Sunday, 03'rd May 2020
It's time to shop for healthcare stocks that have suffered so far this year but should rebound in the long term thanks to growth drivers waiting in the wings. The first of these great deals, a pharma
We expect CVS Health (CVS) to have gained from Aetna's addition of new Individual and Group Medicare Advantage members in Q1.
We expect CVS Health (CVS) to have gained from Aetna's addition of new Individual and Group Medicare Advantage members in Q1.
InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
Varian's (VAR) solid Oncology platform is expected to have driven fiscal second-quarter performance.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE